Showing results (11-20 of 33) with videos related to
Sort By:
Pageof 4
Journal of Clinical Gastroenterology|December 20, 2007
Selective leukocyte apheresis for the treatment of inflammatory bowel diseaseMaria T Abreu, Scott Plevy, Bruce E Sands, et al.Journal of Crohn'S & Colitis|September 9, 2016
Are We Ready to Abandon Placebo in Randomised Clinical Trials for Inflammatory Bowel Disease? Pros and ConsSilvio Danese, Elmer Schabel, Johan Masure, et al.Inflammatory Bowel Diseases|January 28, 2005
Cigarette smoking and age at diagnosis of inflammatory bowel diseaseMiguel Regueiro, Kevin E Kip, Onki Cheung, et al.The American Journal of Gastroenterology|August 9, 2003
Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel diseaseMiguel Regueiro, John Valentine, Scott Plevy, et al.The Journal of Biological Chemistry|July 24, 2003
Activation of the murine interleukin-12 p40 promoter by functional interactions between NFAT and ICSBPChen Zhu, Kavitha Rao, Huabao Xiong, et al.The American Journal of Gastroenterology|June 24, 2003
The incidence and management of infusion reactions to infliximab: a large center experienceAdam Cheifetz, Michelle Smedley, Sara Martin, et al.Crohn'S & Colitis 360|February 13, 2023
Opioid Use in Patients With Inflammatory Bowel DiseaseXiwu Lin, Jennifer Lofland, Ling Zhang, et al.The Journal of Experimental Medicine|December 15, 2010
Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murinaRekha R Rapaka, David M Ricks, John F Alcorn, et al.Inflammatory Bowel Diseases|March 23, 2013
Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patientsScott Plevy, Mark S Silverberg, Steve Lockton, et al.Gastroenterology|October 9, 2007
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitisScott Plevy, Bruce Salzberg, Gert Van Assche, et al.Pageof 4